ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)

被引：1
|
作者：
Johnson, Peter W. M. [1 ]
Caddy, Joshua [2 ]
Cumin, Tom [1 ]
Merton, Bridgen [1 ]
Maishman, Tom [2 ]
Galanopoulou, Angelic [2 ]
Griffiths, Gareth [2 ]
Davies, Andrew [1 ]
机构：
[1] CRUK Ctr, Southampton, Hants, England
[2] Southampton Clin Trials Unit, Southampton, Hants, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT162
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
    Davies, Andrew
    Caddy, Josh
    Mercer, Katy
    Saunders, Geoff N.
    Stanton, Louise
    Collins, Graham P.
    Cummin, Thomas E. C.
    Schuh, Anna
    Ardeshna, Kirit M.
    McMillan, Andrew
    Radford, John A.
    Lewis, David John
    Coleman, Adam
    Griffiths, Gareth
    Burton, Cathy
    Barrans, Sharon
    Johnson, Peter
    BLOOD, 2020, 136
  • [2] Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
    Davies, Andrew J.
    Caddy, Josh
    McLaughlin, Katy
    Wignall, Christopher
    Waugh, Robert
    Collins, Graham P.
    Stanton, Louise
    Saunders, Geoff N.
    Cummin, Thomas
    Schuh, Anna
    Ardeshna, Kirit M.
    McMillan, Andrew K.
    Radford, John
    Lewis, David John
    Coleman, Adam R.
    Griffiths, Gareth
    Burton, Cathy
    Barrans, Sharon
    Johnson, Peter
    BLOOD, 2022, 140 : 9478 - 9479
  • [3] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
    Candelaria, Myrna
    Duenas-Gonzalez, Alfonso
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [4] OUTCOMES IN PATIENTS WITH PRIMARY GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA AFTER RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) CHEMOTHERAPY
    Suh, C.
    Sohn, B. S.
    Yoon, D. H.
    Kim, S.
    Lee, D. H.
    Kim, S. W.
    Huh, J. R.
    Lee, J. S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 650 - 650
  • [5] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy
    Sohn, B.
    Yoon, D.
    Kim, S.
    Lee, D.
    Kim, S.
    Huh, J.
    Lee, J.
    Suh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Pharmacokinetic and pharmacodynamic evaluation of a biosimilar rituximab in newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone)
    Viswabandya, Auto
    Prashanthi, P. V.
    Raju, C. Nirmala
    Rajsekhar, Reena
    Mathews, Vikram
    Madki, Shivkumar
    Abhayankar, Dhiraj
    Kethireddypally, Rukmini
    George, Biju
    Chandy, Mammen
    Reddy, Cartikeya
    Srivastava, Alok
    BLOOD, 2007, 110 (11) : 194B - 194B
  • [7] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
    Sawalha, Yazeed
    Welkie, Rina Li
    Krivenko, Anna
    Hess, Brian
    Sigmund, Audrey M.
    Voorhees, Timothy
    Hanel, Walter
    Bond, David A.
    Reneau, John C.
    Epperla, Narendranath
    Alinari, Lapo
    Brammer, Jonathan E.
    Christian, Beth
    Baiocchi, Robert
    Maddocks, Kami J.
    BLOOD, 2023, 142
  • [8] Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma
    Wöhrer, S
    Püspök, A
    Drach, J
    Hejna, M
    Chott, A
    Raderer, M
    ANNALS OF ONCOLOGY, 2004, 15 (07) : 1086 - 1090
  • [9] Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment of primary gastrointestinal B-cell lymphoma
    Aguiar Bujanda, D.
    Cabrera Suarez, M. A.
    Llorca Martinez, I.
    Bohn Sarmiento, U.
    Saura Grau, S.
    Rodriguez Franco, C.
    Aguiar Morales, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
    Dietrich, S.
    Tilly, H.
    Morschhauser, F.
    Sehn, L. H.
    Friedberg, J.
    Trneny, M.
    Sharman, J. P.
    Herbaux, C.
    Burke, J. M.
    Matasar, M.
    Rai, S.
    Izutsu, K.
    Mehta-Shah, N.
    Oberic, L.
    Chauchet, A.
    Jurczak, W.
    Song, Y.
    Greil, R.
    Mykhalska, L.
    Burgues, J. M. B.
    Cheung, M. C.
    Pinto, A.
    Shin, H-J
    Hapgood, G.
    Munhoz, E.
    Abrisqueta, P.
    Gau, J-P
    Hirata, J.
    Jiang, Y.
    Yan, M.
    Lee, C.
    Flowers, C.
    Salles, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
12345